Video

Ovarian Cancer Developments in 2017

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses recent exciting developments in the ovarian cancer field.

The year 2017 has been an important one for the ovarian cancer field. New drugs have been approved that give hope to people who have tried other therapies but whose cancer has come back.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, shares his thoughts on the exciting developments in his field. Three poly (ADP-ribose) polymerase (PARP) inhibitors were recently approved for people who have ovarian cancer which are administered orally, so they are convenient to take, and may be taken for a long time. He believes patients will benefit greatly from these drugs.

Related Videos
Image of a woman with tied back hair, wearing pearl earrings.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Image of a man wearing a black suit and tie.
Image of a man with white hair and a white goatee.
Image of a woman with brown wavy hair, wearing a navy blue top.
Image of a man wearing a suit with a red bowtie.
Related Content
Image of a DNA strand and "Clinical Trial Corner"
October 8th 2024

First Patient With Ovarian Cancer Receives Peptide-Drug Conjugate in Study

Darlene Dobkowski, MA
This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other solid tumor types.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of ovaries.
September 26th 2024

Cediranib Added to Lynparza Didn’t Improve Progression, Survival in Ovarian Cancer

Ashley Chan
A Lynparza/cediranib combo had similar results versus standalone Lynparza among patients with relapsed platinum-sensitive ovarian cancer.
Shannon Miller smiling at a podium while delivering the keynote address at the 2023 Extraordinary Healer event | Image credit: © ATA-GIRL PHOTOGRAPHY
May 4th 2023

Olympian Shares Her Cancer Experience: ‘Give Yourself Grace’

Brielle Benyon
Olympic gymnast, Shannon Miller, sat down with CURE® to discuss her experience with a rare type of ovarian cancer, and how her competitive mindset helped her through.
Picture of Dr. Guillermo Garcia-Manero
September 18th 2024

Why Transfusion Independence Matters for Patients With MDS

Alex Biese
An expert explained the burden that red blood cell transfusions can place on patients with MDS.
Illustration of a woman with medium-length blonde hair, wearing a patterned scarf.
September 18th 2024

Healing and Reflecting on My Ovarian Cancer Experience

Julie S. Brokaw
The past 15 months have been challenging regarding treatment for my ovarian cancer. But today, my goal is to focus on healing my mind, body and soul.